Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2012
进行中（未招募）
1
100.0%
暂无批准数据
- Phio Pharmaceuticals' PH-762 demonstrated 100% tumor clearance in one patient and greater than 90% clearance in another patient at the maximum dose in its Phase 1b skin cancer trial. - The FDA has accepted the company's nonclinical protocol study design for PH-762, with toxicology studies planned to begin in Q1 2026. - The INTASYL siRNA therapy has shown no dose-limiting toxicities across 18 patients treated in five escalating dose cohorts for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. - Recent warrant financing raised approximately $12.1 million, extending the company's cash runway into the first half of 2027.
- Phio Pharmaceuticals' investigational siRNA therapeutic PH-762 achieved complete tumor clearance in 37.5% of cutaneous squamous cell carcinoma patients in an ongoing Phase 1b trial. - The intratumoral treatment demonstrated a favorable safety profile with no dose-limiting toxicities or immune-related adverse events across a 20-fold dose escalation. - PH-762 utilizes Phio's INTASYL gene silencing platform to target PD-1 locally within tumors, offering a potential non-surgical alternative for skin cancer treatment. - The study enrolled 18 patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with encouraging pathologic response rates supporting continued development.
- Phio Pharmaceuticals announced positive Phase 1b trial results for INTASYL PH-762, with one patient achieving 100% tumor clearance and two others showing greater than 90% and 50% clearance respectively in cutaneous squamous cell carcinoma. - The Safety Monitoring Committee issued a favorable safety review, confirming no dose-limiting toxicities or clinically relevant adverse effects at the maximum dose concentration across all 18 patients treated. - Cumulative results from 16 patients with cutaneous squamous cell carcinoma showed six complete responses, two near complete responses, and two partial responses, highlighting PH-762's potential as a non-surgical treatment option. - The trial evaluated a 20-fold dose increase from the first cohort, with PH-762 demonstrating consistent tolerability without immune-related adverse events throughout dose escalation.
- Phio Pharmaceuticals has entered into a comprehensive drug substance development services agreement with a U.S. manufacturer for its lead compound PH-762, marking a critical advancement in its intratumoral cancer treatment program. - The company is currently enrolling patients for the fifth and expected final cohort in its Phase 1b dose escalation study evaluating PH-762 for cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma. - PH-762 utilizes Phio's proprietary INTASYL gene silencing technology to silence the PD-1 gene and represents a potential non-surgical treatment option for various skin cancers.
- Phio Pharmaceuticals reports two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance in a Phase 1b trial of PH-762. - The ongoing study (NCT 06014086) evaluates the safety and tolerability of intratumoral PH-762 in various stages of skin cancers, including melanoma and Merkel cell carcinoma. - PH-762, utilizing Phio's INTASYL technology, targets PD-1 to enhance immune cell-mediated cancer cell killing, with no dose-limiting toxicities observed. - A partial response, with 90% tumor clearance, was observed in another patient with cutaneous squamous cell carcinoma, indicating promising early results for PH-762.
- Phio Pharmaceuticals has completed enrollment in the second cohort of its Phase 1b dose-escalating clinical trial of PH-762. - Early data from the trial shows one patient with cutaneous squamous cell carcinoma achieved a complete response and another a partial response. - The trial, evaluating intratumorally injected PH-762, now includes six clinical sites across the United States. - PH-762 leverages Phio's INTASYL siRNA technology to silence PD-1, enhancing T cell's ability to kill cancer cells.
- Phio Pharmaceuticals announced data showcasing its INTASYL siRNA technology's ability to enhance immune cell targeting and killing of cancer cells. - INTASYL compounds improve the functionality and outcomes of adoptive cell therapies like NK, TIL, and CAR-T by precisely silencing mRNA. - The platform's efficient delivery system streamlines siRNA delivery to target cells without requiring specialized formulations. - Preclinical data demonstrates that INTASYL compounds targeting PD-1, BRD4, TIGIT, and CBLB enhance anti-tumor immune responses.
